Early-Stage Investments Propel Jump In Life Sciences Venture Capital
This article was originally published in The Tan Sheet & The Rose Sheet
In some cases, early venture capital appears to be substituting for the public market in providing finance not only to start but also sustain companies in specialty pharma and in-licensing, development-only businesses. At least 200 capital groups took part in the 156 recorded A rounds, and 50 participated in more than one.
You may also be interested in...
Since 2013, investors have rallied around biotech IPOs like never before. START-UP looks at the current window and the implications of investor enthusiasm for newly public companies.
Blackrock Neurotech’s MoveAgain technology platform allows patients who have been silenced by ALS, paralysis and other spinal cord injuries the ability to better communicate via text. The device has been granted breakthrough status by the US FDA.
The MITRE corporation and MDIC have produced a manual on how to use cybersecurity threat modeling to make safer medical devices. The document asks four basic questions and provides helpful examples.